Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

被引:62
作者
Barnes, DJ [1 ]
Melo, JV [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Royal Postgrad Med Sch, Fac Med,Dep Haematol, London W12 0NN, England
关键词
chronic myeloid leukaemia; cytogenetics; molecular genetics; oncogenes;
D O I
10.1159/000065655
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic myeloid leukaemia (CML) is caused by the product of the BCR-ABL oncogene, located on the Philadelphia (Ph) chromosome. BCR-ABL is generated as a result of a reciprocal t(9;22) chromosomal translocation. The mechanisms responsible for this illegitimate recombination event remain elusive but are presumed to require a close spatial association of the translocation partners (chromosomes 9 and 22). BCR-ABL fusion transcripts can be detected by a sensitive reverse transcription-polymerase chain reaction (RT-PCR) in the leucocytes of some healthy individuals suggesting that chromosomal translocations may occur frequently in the general population. The presence of BCR-ABL fusion transcripts does not imply that the individual will inevitably develop CML since other conditions must be favourable for expansion of the abnormal clone. Breakpoints in the ABL gene occur within a 5' segment. BCR-ABL fusion transcripts lack ABL exon a 1 and consist of BCR exons fused directly to ABL exon a 2. The breakpoints in the BCR gene on chromosome 22 are found within three defined regions. Depending on the position of the BCR breakpoint, fusion genes are generated that encode 190-, 210- or 230-kD forms of the Bcr-Abl tyrosine kinase. Since the ABL component of the fusion gene is largely invariant, it follows that variability in disease phenotype may be due to protein sequences encoded by the translocation partner, BCR. Different disease phenotypes are associated with each of the three Bcr-Abl oncoproteins, P190(Bcr-Abl), p210(Bcr-Abl) and p230(Bcr-Abl). Mechanisms associated with malignant transformation include altered cellular adhesion, activation of mitogenic signalling pathways, inhibition of apoptosis and proteasomal degradation of physiologically important cellular proteins. CML is subject to an inexorable progression from an 'indolent' chronic phase to a terminal blast crisis. Disease progression is presumed to be associated with the phenomenon of genomic instability. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:180 / 202
页数:23
相关论文
共 184 条
[1]  
ABELSON HT, 1970, CANCER RES, V30, P2213
[2]  
AHMED S, 1994, J BIOL CHEM, V269, P17642
[3]   CML with an e1a3 BCR-ABL fusion:: rare, benign, and a potential diagnostic pitfall [J].
Al-Ali, HK ;
Leiblein, S ;
Kovacs, I ;
Hennig, E ;
Niederwieser, D ;
Deininger, MWN .
BLOOD, 2002, 100 (03) :1092-1093
[4]   Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3 [J].
Amarante-Mendes, GP ;
Kim, CN ;
Liu, L ;
Huang, Y ;
Perkins, CL ;
Green, DR ;
Bhalla, K .
BLOOD, 1998, 91 (05) :1700-1705
[5]   APOPTOSIS IN CHRONIC MYELOID-LEUKEMIA - NORMAL RESPONSES BY PROGENITOR CELLS TO GROWTH-FACTOR DEPRIVATION, X-IRRADIATION AND GLUCOCORTICOIDS [J].
AMOS, TAS ;
LEWIS, JL ;
GRAND, FH ;
GOODING, RP ;
GOLDMAN, JM ;
GORDON, MY .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :387-393
[6]   The juxtaposition of ABL with BCR and risk for fusion may come at the time of BCR replication in late S-Phase [J].
Anastasi, J ;
Moinuddin, R ;
Daugherty, C .
BLOOD, 1999, 94 (03) :1137-1138
[7]  
ARDERN JC, 1993, CLIN LAB HAEMATOL, V15, P253
[8]  
Barnes DJ, 2001, BLOOD, V98, p145A
[9]   TRANSLOCATION OF C-ABL ONCOGENE CORRELATES WITH THE PRESENCE OF A PHILADELPHIA-CHROMOSOME IN CHRONIC MYELOCYTIC-LEUKEMIA [J].
BARTRAM, CR ;
DEKLEIN, A ;
HAGEMEIJER, A ;
VANAGTHOVEN, T ;
VANKESSEL, AG ;
BOOTSMA, D ;
GROSVELD, G ;
FERGUSONSMITH, MA ;
DAVIES, T ;
STONE, M ;
HEISTERKAMP, N ;
STEPHENSON, JR ;
GROFFEN, J .
NATURE, 1983, 306 (5940) :277-280
[10]   Bcr/Abl expression stimulates integrin function in hematopoietic cell lines [J].
Bazzoni, G ;
Carlesso, N ;
Griffin, JD ;
Hemler, ME .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :521-528